Arrowhead Pharmaceuticals Inc (ARWR) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Total Revenue Chart for Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc (ARWR) revenue for FY2025 was USD 829.4M, a 23258.2% change from FY2024. Arrowhead Pharmaceuticals Inc's revenue grew from USD 76.6K in 1997 to USD 829.4M in 2025 (1082871.7% over 28 years). Earnings per share moved from USD -0.44 in 2011 to USD -1.92 in 2023. Revenue compound annual growth rate: 5-year CAGR of 56.6%, 10-year CAGR of 115.6%, 20-year CAGR of 43.7%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$8.67B
Implied Share Price
$61.54
Enterprise Value
$8.84B
Revenue (TTM)
$669.49M
EBITDA
-$200.64M
Profit Margin
-47.79%
Trailing P/E
—
Forward P/E
111.11
Price/Book (MRQ)
20.55
Price/Sales (TTM)
12.98
EV/EBITDA
27.85
EV/Revenue
13.37
Dividend Yield
—
Book Value
$3.30
Free Cash Flow (FY2025)
$156.89M
Free Cash Flow Yield
1.81%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.